According to a recent LinkedIn post from Neuromod Devices Ltd, an educational session on future tinnitus care is scheduled for the American Academy of Audiology 2026 meeting. The session, led by Dr. Laura Bradley Pratesi, is set for Friday, April 24, at 11:15 a.m. and will focus on bimodal neuromodulation and biometric tracking in tinnitus treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that synchronized bimodal neuromodulation, including the FDA-approved Lenire device, will be discussed as part of emerging approaches to support patients with bothersome tinnitus. The content suggests Neuromod Devices is positioning Lenire within mainstream audiology and ENT professional forums, which may help drive clinician awareness and adoption.
For investors, visibility at a major professional conference can be relevant to commercial traction in a specialized medical device niche. Increased engagement with audiologists and hearing clinics could support future revenue growth if it translates into higher prescribing or recommendation rates for Lenire among tinnitus patients.